Vascular endothelial growth factor (VEGF) inhibitors prevent activation of cellular processes promoting angiogenesis and are commonly used in the treatment for renal cell carcinoma as well as metastatic colon and gastric cancer [108]. This evidence concerns the gene VEGFA and renal cell carcinoma.